Cargando…

Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4–6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo

BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is most commonly associated with platinum-based drugs, taxanes, and vinca alkaloids. This prospective study from a single center in Kosovo aimed to evaluate CIPN in 120 patients receiving 4–6 cycles of platinum-based and taxane-based chem...

Descripción completa

Detalles Bibliográficos
Autores principales: Myftiu, Blerim, Hundozi, Zylfije, Sermaxhaj, Faton, Blyta, Afrim, Shala, Nexhmedin, Jashari, Fisnik, Bytyqi, Hasime Qorraj, Hyseni, Ekrem, Kurtishi, Ilir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9443419/
https://www.ncbi.nlm.nih.gov/pubmed/36042691
http://dx.doi.org/10.12659/MSM.937856
_version_ 1784782977279983616
author Myftiu, Blerim
Hundozi, Zylfije
Sermaxhaj, Faton
Blyta, Afrim
Shala, Nexhmedin
Jashari, Fisnik
Bytyqi, Hasime Qorraj
Hyseni, Ekrem
Kurtishi, Ilir
author_facet Myftiu, Blerim
Hundozi, Zylfije
Sermaxhaj, Faton
Blyta, Afrim
Shala, Nexhmedin
Jashari, Fisnik
Bytyqi, Hasime Qorraj
Hyseni, Ekrem
Kurtishi, Ilir
author_sort Myftiu, Blerim
collection PubMed
description BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is most commonly associated with platinum-based drugs, taxanes, and vinca alkaloids. This prospective study from a single center in Kosovo aimed to evaluate CIPN in 120 patients receiving 4–6 cycles of platinum-based and taxane-based chemotherapy. MATERIAL/METHODS: One hundred twenty patients underwent neurological examination and nerve conduction studies (NCS) before chemotherapy, and after 4 to 6 cycles of treatment. Sixty patients were treated with platinum-based chemotherapy, 30 were treated with taxane-based chemotherapy, and 22 patients received a combination of platinum- and taxane-based chemotherapy. The most commonly used platinum-based compounds were oxaliplatin and carboplatin, whereas the most commonly used taxane medications were paclitaxel and docetaxel. Presence of neuropathy was confirmed with neurological examination of electrophysiological criteria applicable for polyneuropathies. Total Neuropathy Score (TNSr) was used to combine clinical and electrophysiological values. RESULTS: Around 90% of patients self-reported neuropathic symptoms, and in 60% of them polyneuropathy was present in NCS. All sensory and motor nerves had significantly lower amplitudes (P<0.01). Platinum-based agents caused more pronounced decrease in ulnar nerve compound motor action potential (CMAP) (P<0.05); when used solely or in combination with taxanes, they caused significant decrease in tibial nerve CMAP (P<0.01). TNSr did not reach statistical significance between groups; only clinical muscle strength showed pronounced weakness in the combined protocol (P<0.05). CONCLUSIONS: These findings support previous studies and show that CIPN, including sensory and motor symptoms, is commonly associated with chemotherapy. Platinum-based chemotherapy agents were more commonly associated with ulnar and tibial nerve damage in this study population.
format Online
Article
Text
id pubmed-9443419
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-94434192022-10-20 Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4–6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo Myftiu, Blerim Hundozi, Zylfije Sermaxhaj, Faton Blyta, Afrim Shala, Nexhmedin Jashari, Fisnik Bytyqi, Hasime Qorraj Hyseni, Ekrem Kurtishi, Ilir Med Sci Monit Clinical Research BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is most commonly associated with platinum-based drugs, taxanes, and vinca alkaloids. This prospective study from a single center in Kosovo aimed to evaluate CIPN in 120 patients receiving 4–6 cycles of platinum-based and taxane-based chemotherapy. MATERIAL/METHODS: One hundred twenty patients underwent neurological examination and nerve conduction studies (NCS) before chemotherapy, and after 4 to 6 cycles of treatment. Sixty patients were treated with platinum-based chemotherapy, 30 were treated with taxane-based chemotherapy, and 22 patients received a combination of platinum- and taxane-based chemotherapy. The most commonly used platinum-based compounds were oxaliplatin and carboplatin, whereas the most commonly used taxane medications were paclitaxel and docetaxel. Presence of neuropathy was confirmed with neurological examination of electrophysiological criteria applicable for polyneuropathies. Total Neuropathy Score (TNSr) was used to combine clinical and electrophysiological values. RESULTS: Around 90% of patients self-reported neuropathic symptoms, and in 60% of them polyneuropathy was present in NCS. All sensory and motor nerves had significantly lower amplitudes (P<0.01). Platinum-based agents caused more pronounced decrease in ulnar nerve compound motor action potential (CMAP) (P<0.05); when used solely or in combination with taxanes, they caused significant decrease in tibial nerve CMAP (P<0.01). TNSr did not reach statistical significance between groups; only clinical muscle strength showed pronounced weakness in the combined protocol (P<0.05). CONCLUSIONS: These findings support previous studies and show that CIPN, including sensory and motor symptoms, is commonly associated with chemotherapy. Platinum-based chemotherapy agents were more commonly associated with ulnar and tibial nerve damage in this study population. International Scientific Literature, Inc. 2022-08-31 /pmc/articles/PMC9443419/ /pubmed/36042691 http://dx.doi.org/10.12659/MSM.937856 Text en © Med Sci Monit, 2022 https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Clinical Research
Myftiu, Blerim
Hundozi, Zylfije
Sermaxhaj, Faton
Blyta, Afrim
Shala, Nexhmedin
Jashari, Fisnik
Bytyqi, Hasime Qorraj
Hyseni, Ekrem
Kurtishi, Ilir
Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4–6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo
title Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4–6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo
title_full Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4–6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo
title_fullStr Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4–6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo
title_full_unstemmed Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4–6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo
title_short Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4–6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo
title_sort chemotherapy-induced peripheral neuropathy (cipn) in patients receiving 4–6 cycles of platinum-based and taxane-based chemotherapy: a prospective, single-center study from kosovo
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9443419/
https://www.ncbi.nlm.nih.gov/pubmed/36042691
http://dx.doi.org/10.12659/MSM.937856
work_keys_str_mv AT myftiublerim chemotherapyinducedperipheralneuropathycipninpatientsreceiving46cyclesofplatinumbasedandtaxanebasedchemotherapyaprospectivesinglecenterstudyfromkosovo
AT hundozizylfije chemotherapyinducedperipheralneuropathycipninpatientsreceiving46cyclesofplatinumbasedandtaxanebasedchemotherapyaprospectivesinglecenterstudyfromkosovo
AT sermaxhajfaton chemotherapyinducedperipheralneuropathycipninpatientsreceiving46cyclesofplatinumbasedandtaxanebasedchemotherapyaprospectivesinglecenterstudyfromkosovo
AT blytaafrim chemotherapyinducedperipheralneuropathycipninpatientsreceiving46cyclesofplatinumbasedandtaxanebasedchemotherapyaprospectivesinglecenterstudyfromkosovo
AT shalanexhmedin chemotherapyinducedperipheralneuropathycipninpatientsreceiving46cyclesofplatinumbasedandtaxanebasedchemotherapyaprospectivesinglecenterstudyfromkosovo
AT jasharifisnik chemotherapyinducedperipheralneuropathycipninpatientsreceiving46cyclesofplatinumbasedandtaxanebasedchemotherapyaprospectivesinglecenterstudyfromkosovo
AT bytyqihasimeqorraj chemotherapyinducedperipheralneuropathycipninpatientsreceiving46cyclesofplatinumbasedandtaxanebasedchemotherapyaprospectivesinglecenterstudyfromkosovo
AT hyseniekrem chemotherapyinducedperipheralneuropathycipninpatientsreceiving46cyclesofplatinumbasedandtaxanebasedchemotherapyaprospectivesinglecenterstudyfromkosovo
AT kurtishiilir chemotherapyinducedperipheralneuropathycipninpatientsreceiving46cyclesofplatinumbasedandtaxanebasedchemotherapyaprospectivesinglecenterstudyfromkosovo